Study to Evaluate Blood and Urine Kidney Injury Markers to Facilitate Early Detection of Renal Adverse Drug Events in Pediatric Cancer Patients Treated With Nephrotoxic Chemotherapy

  • STATUS
    Recruiting
  • End date
    Aug 27, 2022
  • participants needed
    23
  • sponsor
    University Hospital, Basel, Switzerland
Updated on 27 January 2021
renal function
cancer
blood test
renal injury
renal function test

Summary

This study is to investigate blood and urine kidney injury markers (especially Uromodulin) in pediatric cancer patients treated with nephrotoxic chemotherapy. Uromodulin is a marker to detect and monitor tubular injury and renal function.

Details
Condition Renal Impairment, Renal Dysfunction, Impaired Renal Function, Kidney Impairment, kidney insufficiency
Treatment blood test for renal biomarkers, urine test for renal biomarkers
Clinical Study IdentifierNCT04308642
SponsorUniversity Hospital, Basel, Switzerland
Last Modified on27 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

signed informed consent by their-selves ( 14 years) or their legal representatives (< 14 years or in case of lacking capacity of judgement)
cancer diagnosis, that indicates a nephrotoxic chemotherapy including the drugs High Dose MTX (HD-MTX), ifosfamide, cis- and carboplatin

Exclusion Criteria

critically-ill patients with inotropic and/or vasopressor drugs
signs of severe Sepsis
receiving other nephrotoxic drugs parallel to the chemotherapy cycle
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note